Key result
Constitutively active PI3-kinase attenuated PKCbeta2 protein expression and improved cardiac function in transgenic mice, suggesting it acts as an upstream modulator of PKCbeta2.
PI3-kinase regulates physiological developmental hypertrophy and may act as an upstream modulator of PKCbeta2, potentially rescuing pathological cardiac dysfunction induced by PKCbeta2 overexpression.
May support PI3K-PKCβ2 targeting in cardiac dysfunction; leaves open translation from transgenic models to clinical use.
The phosphoinositide 3-kinase (PI3-kinase)-protein kinase B (Akt) signaling pathway is essential in the induction of physiological cardiac hypertrophy. In contrast, protein kinase C beta2 (PKCbeta2) is implicated in the development of pathological cardiac hypertrophy and heart failure. Thus far, no clear association has been demonstrated between these two pathways. In this study, we examined the potential interaction between the PI3-kinase and PKCbeta2 pathways by crossing transgenic mice with cardiac specific expression of PKCbeta2, constitutively active (ca) PI3-kinase, and dominant-negative (dn) PI3-kinase. In caPI3-kinase/PKCbeta2 and dnPI3-kinase/PKCbeta2 double-transgenic mice, the heart weight-to-body weight ratios and cardiomyocyte sizes were similar to those observed in caPI3-kinase and dnPI3-kinase transgenic mice, respectively, suggesting that the regulation of physiological developmental hypertrophy via modulation of cardiomyocyte size proceeds through the PI3-kinase pathway. In addition, we observed that caPI3-kinase/PKCbeta2 mice showed improved cardiac function while the function of dnPI3-kinase/PKCbeta2 mice was similar to that of the PKCbeta2 group. PKCbeta2 protein levels in both dnPI3-kinase/PKCbeta2 and PKCbeta2 mice were significantly upregulated. Interestingly, however, PKCbeta2 protein expression was significantly attenuated in caPI3-kinase/PKCbeta2 mice. PI3-kinase activity measured by Akt phosphorylation was not affected by PKCbeta2 overexpression. These data suggest a potential interaction between these two pathways in the heart, where PI3-kinase is predominantly responsible for the regulation of physiological developmental hypertrophy and may act as an upstream modulator of PKCbeta2 with the potential for rescuing the pathological cardiac dysfunction induced by overexpression of PKCbeta.
No takes yet. Share an insight, caveat, or question.
Rigor et al. (2009) studied Cardiac hypertrophy. Constitutively active (ca) and dominant-negative (dn) PI3-kinase vs. PKCbeta2 overexpression was evaluated on Heart weight-to-body weight ratios, cardiomyocyte sizes, and cardiac function. Constitutively active PI3-kinase attenuated PKCbeta2 protein expression and improved cardiac function in transgenic mice, suggesting it acts as an upstream modulator of PKCbeta2.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: